Ozekibart / FDA decision

Research only

Rx-INBX-2704 · April 14, 2027 sponsor target

Sponsor source Resolution draft Program evidence

Event question

Will the FDA approve Ozekibart for unresectable or metastatic conventional chondrosarcoma?

Filing reports BLA acceptance for ozekibart in conventional chondrosarcoma and an April 14, 2027 FDA target.

Sponsor target: April 14, 2027
Source published: Jun 15, 2026
Research snapshot: Oct 28, 2026
Trading status: Research / unlisted

A PDUFA goal date is not an approval determination or a trading cutoff. Application scope, delays and invalid-result terms require reviewed rules.

Published evidence

1 publications1 exact-program0 related2 context / correction notes

Review publications

Sources

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sec-filingwww.sec.gov

Filing reports BLA acceptance for ozekibart in conventional chondrosarcoma and an April 14, 2027 FDA target.

Published: Jun 15, 2026
Retrieved: 2026-10-30 02:09:48 UTC

sec-exhibitwww.sec.gov

Sponsor describes ozekibart as a tetravalent DR5 agonist antibody and identifies the ChonDRAgon registrational study.

Published: Jun 15, 2026
Retrieved: 2026-10-30 02:09:48 UTC

clinical-trial-registryclinicaltrials.gov

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.

Published: Not supplied
Retrieved: 2026-10-30 02:09:48 UTC

Resolution not committed

This research candidate has no onchain question, committed rule hash or funded pool.

Draft outcome criteria

These terms require review and cannot resolve a market.

YES: Approval of the exact application, formulation and eligible indication, established under the reviewed evidence hierarchy. Application and label scope still require review.
NO: Final terms must specify a Complete Response Letter, withdrawal, extension and no decision by cutoff. The sponsor’s target date alone cannot establish NO.
INVALID: Final terms must specify ambiguous identity, erroneous dates and unsupported evidence. No policy has been committed for this candidate.

Read the full research draft

RESEARCH DRAFT / NOT FINAL RULES / NOT COMMITTED

Program: Ozekibart
Sponsor: Inhibrx Biosciences
Indication under review: unresectable or metastatic conventional chondrosarcoma
Event: FDA marketing-approval decision
Sponsor target: 2027-04-14 (date only, not a trading cutoff)

YES: FDA approval of the exact application, formulation and eligible indication, established under a reviewed evidence hierarchy. Exact application/label scope requires review.

NO: The approved market terms must specify treatment of a Complete Response Letter, withdrawal, extension and no decision by cutoff. No automatic NO outcome is inferred from the sponsor target date.

INVALID: The approved terms must specify erroneous dates, ambiguous identity, unsupported evidence and withdrawal handling. No policy has been committed for this candidate.

Cutoff and timezone: UNSET / OWNER APPROVAL REQUIRED.
Evidence: FDA approval letter or other authoritative FDA record; sponsor disclosures require the corroboration specified in final rules.
Oracle: assertion, dispute bond, liveness and final settlement require separately reviewed deployment settings.

This draft cannot resolve a market or pay a claim. Publish reviewed canonical bytes and their keccak256 commitment before listing.

No question ID, approved deadline or UMA assertion exists for this research candidate. Sandbox claims have no redemption rights.